IP Library Granted Patent US 7,812,011
Granted Patent B2
US 7,812,011 · App. 10/590,848 · Granted Oct 12, 2010

Steroid agonist for FXR

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,812,011
App. No.
10/590,848
Granted
Oct 12, 2010
Kind
B2
Abstract

The invention relates to a FXR agonist of formula (I) and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.

Claims (12)

1. A compound of formula (I):

and pharmaceutically acceptable salts or amino acid conjugates thereof.

2. The glycine conjugate of the compound of formula (I):

3. The taurine conjugate of the compound of formula (I):

4. The compound of claim 1 , wherein said compound is radiolabeled.

5. The compound of claim 4 , wherein said compound is tritiated.

6. A pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

7. A method for the treatment of an FXR mediated disease or condition in a mammal comprising administering to a mammal suffering from an FXR mediated disease or condition a therapeutically effective amount of a compound according to claim 1 , wherein said FXR mediated disease or condition is selected from the group consisting of hypercholesteremia, hyperlipidemia, low HDL-cholesterol, and high triglycerides.

8. A method for the treatment of cardiovascular disease in a mammal comprising administering to a mammal suffering from a cardiovascular disease a therapeutically effective amount of a compound according to claim 1 , wherein said cardiovascular disease is selected from the group consisting of artherosclerosis and hypercholesteremia.

9. The method according to claim 8 , wherein said cardiovascular disease is artherosclerosis.

10. A method for increasing HDL cholesterol in a mammal, said method comprising administering to a mammal whose HDL cholesterol is to be increased a therapeutically effective amount of a compound according to claim 1 .

11. A method for lowering triglycerides in a mammal, said method comprising administering to a mammal whose triglycerides are to be lowered a therapeutically effective amount of a compound according to claim 1 .

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0877 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2007
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 019592/0153 →